Boston Family Office LLC Sells 2,868 Shares of Bristol-Myers Squibb (NYSE:BMY)

Boston Family Office LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMYFree Report) by 9.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,533 shares of the biopharmaceutical company’s stock after selling 2,868 shares during the period. Boston Family Office LLC’s holdings in Bristol-Myers Squibb were worth $1,361,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of BMY. Addison Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 6.6% during the third quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 192 shares during the last quarter. Symphony Financial Ltd. Co. increased its holdings in Bristol-Myers Squibb by 4.1% in the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 194 shares during the period. AMG National Trust Bank increased its holdings in Bristol-Myers Squibb by 1.0% in the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock valued at $1,143,000 after purchasing an additional 201 shares during the period. Westside Investment Management Inc. increased its holdings in Bristol-Myers Squibb by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 204 shares during the period. Finally, Fulton Breakefield Broenniman LLC increased its holdings in Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 209 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Down 0.2 %

NYSE BMY traded down $0.07 during trading hours on Wednesday, hitting $40.42. The company’s stock had a trading volume of 10,913,643 shares, compared to its average volume of 15,464,375. Bristol-Myers Squibb has a 52 week low of $39.94 and a 52 week high of $66.46. The company has a market capitalization of $81.94 billion, a PE ratio of -12.94, a price-to-earnings-growth ratio of 13.96 and a beta of 0.45. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The company’s 50-day simple moving average is $47.36 and its two-hundred day simple moving average is $49.49.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter last year, the firm earned $2.05 EPS. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Research analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.94%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. BMO Capital Markets decreased their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Barclays decreased their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.00.

Check Out Our Latest Analysis on Bristol-Myers Squibb

Bristol-Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See Also

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.